1. Field of the Invention
The present invention in various embodiments relates to assessing the value of assets.
2. Description of the Related Art
Patents play an important role in our economy in encouraging private investment in new ideas and the development of new technologies that improve productivity and quality of life for everyone. Each year more than a quarter-million patent applications are filed in the United States Patent and Trademark Office (“PTO”), resulting in the issuance of over a hundred fifty-thousand patents annually. Patent owners and applicants pay combined fees and costs of over a billion dollars per year to the PTO to obtain and maintain their patents and applications. See, United States Patent & Trademark Office, FY 2000 USPTO Annual Report. Additional fees and costs are typically incurred for related professional services, such as attorneys fees, search fees, drafting charges and the like.
A recent survey conducted by the American Intellectual Property Law Association (“AIPLA”) reported that the median fees charged by law firms for preparing and filing original utility patent applications in 1999 ranged between $4,008 and $7,993, depending upon subject matter and complexity. See, American Intellectual Property Law Association, Report of Economic Survey, pp. 63-63 (1999). In addition, patent owners bring thousands of infringement suits each year in the federal courts. In the twelve months ending June 1998 a total of 1,996 patent-related cases were filed in the United States Federal District Courts. See, Annual Report of Judicial Statistics for 1997, Vol. 1, Civil Cases. The median cost of these suits in 1999 was estimated at $1.5 million per side through trial and appeal. It can be conservatively estimated that the total aggregate costs for obtaining, maintaining and enforcing patents in 1999 exceeded about $5.5 billion.
Because of the great importance of patents in the both the U.S. and global economies there has been continued interest in quantifying the value of patents and their contribution to economic prosperity of the individuals or companies that hold and/or control them. Such information can be useful for a variety of purposes. For example, patent holders themselves may be interested in using such information to help guide future decision-making or for purposes of tax treatment, transfer pricing or settlement of patent license disputes. Financial advisors and investors may seek to use such information for purposes of comparative value analysis and/or to construct measures of the “fundamental value” of publicly traded companies for purposes of evaluating possible strategic acquisitions or as a guide to investment. Economists may seek to use patent valuations for purposes of economic forecasting and planning. Insurance carriers may use such valuations to set insurance policy premiums and the like for insuring intangible assets. See, e.g., U.S. Pat. No. 6,018,714, incorporated herein by reference.
However, accurate valuing of patents and other intangible intellectual property assets is a highly difficult task requiring an understanding of a broad range of legal, technical and accounting disciplines. Intellectual property assets are rarely traded in open financial markets or sold at auction. They are intangible assets that secure unique benefits to the individuals or companies that hold them and/or exploit the underlying products or technology embodying the intellectual property. In the case of patent assets, for example, this unique value may manifest itself in higher profit margins for patented products, increased market power and/or enhanced image or reputation in the industry and/or among consumers or investors. These and other characteristics of intellectual property assets make such assets extremely difficult to value.
Patents derive unique value from the legal rights they secure, namely the right to exclude competition in the patented technology. This value (if any) usually manifests itself as a net increase in operating revenues resulting from either: (i) premium pricing of patented products or services; or (ii) royalty payments or other valuable consideration paid by competitors or other parties for use of the patented technology. Given these two inputs and the timing and probability of anticipated future revenue streams, an experienced valuation professional can readily estimate the value of a patent. See, Smith & Par, Valuation of Intellectual Property and Intangible Assets, 2nd Ed. (1989).
A familiar scenario is a patent licensed to a third party under an exclusive agreement that guarantees a predetermined income stream over a certain period of time. Using an income valuation approach, the intrinsic value of the licensed patent can be calculated simply as the net discounted present value of the future projected cash flows. Similarly, if the patent owner is exploiting the patented technology itself, the value of the patent may be fairly estimated as the net discounted present value of the incremental profit stream (assuming one can be identified) attributable to the patent over the remaining life of the patent or the economic life of the patented technology, whichever is shorter.
In these and similar scenarios where specific anticipated economic benefits can be identified and attributed to a particular intellectual property asset, accurate and credible estimations of value can be calculated using a traditional income valuation approach. In many cases, however, it is exceedingly difficult to identify with a desired degree of certainty a definite income stream or other anticipated economic benefit attributable to a particular intellectual property asset of interest. The classic example is a newly issued patent or an existing patent covering technology that, for whatever reason, has yet to be commercialized. In these and similar cases involving “unproven” patent assets the income valuation approach is less useful. The more tenuous the connection is between current revenues and anticipated future revenues, the more speculative the income valuation approach becomes.
For example, one popular approach involves guestimating “hypothetical” future license fees or royalties based on available data obtained from private license agreements and/or litigation settlements/awards involving patents in a similar technical field. While such analysis may be useful in certain cases, it suffers from several drawbacks that can lead to significant inaccuracies. One drawback is the inherent selection bias in the comparative data used to calculate hypothetical future license fees or royalties. By definition, all of the patents in the comparison group have been licensed, litigated and/or otherwise commercialized. This creates a “high-value” selection bias because most patents within the general population of patents are never licensed, litigated or commercialized at all. Thus, the approach will tend to over-value many patent assets. The approach also does not attempt to distinguish between similar patents based on underlying quality, breadth of claims, etc. Rather, the approach assumes that patents are fungible assets and that any one patent has essentially the same income earning potential as any other patent within the same field.
The reality is that every patent is unique. There are good patents and bad patents; broad patents and narrow patents; patents that are well-drafted and prosecuted and others that are not so well-drafted or prosecuted. Two patents in the same industry and relating to the same general subject matter can command drastically different royalty rates in a free market (or damage awards in litigation) depending upon subtle differences that affect the comparative breadth and defensibility of each patent.
Where there is enough money at stake, one or more patent lawyers can be engaged to analyze an individual patent and render a legal opinion, including an assessment of overall patent quality. But, such qualitative assessments are difficult to quantify in a way that lends itself to patent valuation analysis. Legal opinions are also inherently subjective, leaving the possibility for inconsistencies in assessed patent quality from attorney to attorney or from firm to firm.
What is needed is a purely objective approach for comparatively rating and valuing patents (particularly unproven patent assets) in a way that overcomes the above-noted problems and limitations.
Some embodiments of the invention include a method for constructing an estimated depreciation schedule for a patent. The steps for constructing this schedule may include: (1) determining a first function which approximately describes the rate of initial increase in expected forward patent citations over time; (2) determining a second function which approximately describes the rate of eventual decay in expected forward patent citations over time; and (3) constructing an estimated depreciation schedule using a calculated decay coefficient derived from said second function.
In some embodiments the first function comprises a lognormal probability distribution function. In some embodiments, the forward citation frequency is approximated by the product of the first and second functions.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention. Certain preferred embodiments and examples will now be described in detail having reference to the figures that follow, of which:
In valuing a patent asset, a time-wise adjustment needs to be made in order to account for the effects of value depreciation over time. Depreciation of patent value over time may be caused by: (i) depletion of remaining patent term; and (ii) obsolescence over time of the underlying patented technology. A discussion on the valuation of patents can be found in U.S. Pat. No. 6,556,992, which is hereby incorporated herein by reference.
Term depletion depreciation accounts for loss of patent value due to exhausting the useful life of the patent. Every patent has a finite maximum term, averaging about 17.3 years. Depletion of patent term results in corresponding depletion of value because there is less time to extract the economic benefits of the patent and the underlying technology. This can generally be approximated as a straight line depreciation function over the expected patent term.
In addition to term depletion there is also loss of value due to age-related obsolescence of the underlying patented technology. In a licensing context, this can be thought of as time-wise diminishment or dilution of the “royalty base” caused by the introduction of new improvement patents that ultimately compete for the same royalty dollars. In some embodiments, the rate at which newer patents (and technology) replace older patents (and technology) is used as the rate of patent obsolescence.
In one embodiment, the average rate at which patents and technology become obsolete (e.g. replaced by newer technology and patents) assists in determining an appropriate patent depreciation schedule (i.e., how quickly a patent will lose value over time). Advantageously, the rate of patent obsolescence may also be used to formulate a patent filing and prosecution strategy and to set target benchmarks.
In some embodiments of the invention, the patent obsolescence rate is estimated by measuring the decline in the rate of forward citations of aging patents. As technological advances are made and as new patents are filed and issued, older patents gradually become less and less relevant to the newer patents that represent the latest, leading edge technology. This may be reflected by a declining rate of citations from newer patents to older patents. Eventually, older patents may cease receiving citations altogether as the older technologies gradually fade away and are replaced with newer technologies. This phenomenon is illustrated in
P(cite)=LOGNORMDIST(AGE,LOGMEAN,LOGSTDV)
Where:
P(cite)=probability of citation
AGE=patent age in years=int(PatentAge)+1 or “Age of Cited+1”
LOGMEAN=log mean of the lognormal distribution
LOGSTDV=log standard deviation of the lognormal distribution
In some embodiments of the invention, the decline in forward citation rates over time (the next 5-20 years) generally follows an exponential decay function. In some embodiments,
FWDCITES(normalized)=STARTVALUE*EXP(AGE*DECAYRATE)
Where:
FWD CITES (normalized)=number of forward cites normalized as a percentage of the yearly maximum
STARTVALUE=hypothetical initial start value of FWD CITES (normalized)
DECAYRATE=decay coefficient of the exponential decay function
In some embodiments, the actual observed forward citation frequency is closely approximated by the product of the lognormal ramp-up function (plot titled “Ramp Up” and marked with squares,
One example of this calculation is provided in the table of
The above calculation is merely an example and should not be construed to limit the scope of the invention. The square of the Pearson product moment correlation coefficient (“RSQ”) in this case was equal to 0.996, indicating that the model provided a very good fit, as illustrated in
In this case the exponent of the citation frequency decay function was iteratively determined to be −0.09954, indicating an average rate (or risk) of obsolescence of 9.95% per year. This corresponds to a technology half-life of 6.96 years. This suggests that the average utility or value of a patent selected from the peer group would decay to ½ of its original starting value after 6.96 years (ignoring the added effects of term depletion). In some embodiments, a technology's half-life is calculated by the following equation:
The data included in the above example can be further described as follows:
The rate of patent obsolescence varies from technology to technology. Typically, faster-paced technologies, such as computer-electronics and software, decline more rapidly than slower-paced technologies, such as basic materials and simple mechanical technologies. Data on the obsolescence of a few exemplary US patent classifications resulting from one embodiment of the invention are provided below:
Some embodiments of the invention may provide all or some of the following advantages:
In some embodiments, it is contemplated that some or all of the steps described herein may be implemented within, or using, software modules (programs) that are executed by one or more general purpose computers. In these embodiments, the software modules may be stored on or within any suitable computer-readable medium. It should be understood that the various steps may alternatively be implemented in-whole or in-part within specially designed hardware.
Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above.
This application claims the benefit of U.S. Provisional Application No. 60/714,713, filed Sep. 7, 2005, the entirety of which is hereby incorporated by reference
Number | Name | Date | Kind |
---|---|---|---|
4991087 | Burkowski et al. | Feb 1991 | A |
5175681 | Iwai et al. | Dec 1992 | A |
5392390 | Crozier | Feb 1995 | A |
5544302 | Nguyen | Aug 1996 | A |
5546529 | Bowers et al. | Aug 1996 | A |
5576954 | Driscoll | Nov 1996 | A |
5594897 | Goffman | Jan 1997 | A |
5608620 | Lundgren | Mar 1997 | A |
5615362 | Jensen et al. | Mar 1997 | A |
5625814 | Luciw | Apr 1997 | A |
5640553 | Schultz | Jun 1997 | A |
5642502 | Driscoll | Jun 1997 | A |
5680305 | Apgar, IV | Oct 1997 | A |
5694592 | Driscoll | Dec 1997 | A |
5721903 | Anand | Feb 1998 | A |
5754840 | Rivette et al. | May 1998 | A |
5764058 | Itskovich et al. | Jun 1998 | A |
5774833 | Newman | Jun 1998 | A |
5778362 | Deerwester | Jul 1998 | A |
5781773 | Vanderpool et al. | Jul 1998 | A |
5794236 | Mehrle | Aug 1998 | A |
5799325 | Rivette et al. | Aug 1998 | A |
5802501 | Graff | Sep 1998 | A |
5808615 | Hill et al. | Sep 1998 | A |
5848409 | Ahn | Dec 1998 | A |
5893092 | Driscoll | Apr 1999 | A |
5926811 | Miller et al. | Jul 1999 | A |
5930784 | Hendrickson | Jul 1999 | A |
5937402 | Pandit | Aug 1999 | A |
5991751 | Rivette et al. | Nov 1999 | A |
5999907 | Donner | Dec 1999 | A |
6009436 | Motoyama et al. | Dec 1999 | A |
6014663 | Rivette et al. | Jan 2000 | A |
6018714 | Risen, Jr. et al. | Jan 2000 | A |
6018749 | Rivette et al. | Jan 2000 | A |
6038561 | Snyder et al. | Mar 2000 | A |
6038574 | Pitkow et al. | Mar 2000 | A |
6049811 | Petruzzi et al. | Apr 2000 | A |
6088692 | Driscoll | Jul 2000 | A |
6108651 | Guha | Aug 2000 | A |
6154725 | Donner | Nov 2000 | A |
6175824 | Breitzman et al. | Jan 2001 | B1 |
6182091 | Pitkow et al. | Jan 2001 | B1 |
6202058 | Rose et al. | Mar 2001 | B1 |
6212530 | Kadlec | Apr 2001 | B1 |
6216134 | Heckerman et al. | Apr 2001 | B1 |
6263314 | Donner | Jul 2001 | B1 |
6285999 | Page | Sep 2001 | B1 |
6286018 | Pitkow et al. | Sep 2001 | B1 |
6289342 | Lawrence et al. | Sep 2001 | B1 |
6298327 | Hunter et al. | Oct 2001 | B1 |
6330547 | Martin | Dec 2001 | B1 |
6339767 | Rivette et al. | Jan 2002 | B1 |
6363373 | Steinkraus | Mar 2002 | B1 |
6389418 | Boyack et al. | May 2002 | B1 |
6389436 | Chalrabarti et al. | May 2002 | B1 |
6421066 | Sivan | Jul 2002 | B1 |
6452613 | Lefebvre et al. | Sep 2002 | B1 |
6453315 | Weissman et al. | Sep 2002 | B1 |
6457028 | Pitkow et al. | Sep 2002 | B1 |
6463431 | Schmitt | Oct 2002 | B1 |
6490548 | Engel | Dec 2002 | B1 |
6526440 | Bharat | Feb 2003 | B1 |
6556992 | Barney et al. | Apr 2003 | B1 |
6560600 | Broder | May 2003 | B1 |
6571241 | Nosohara | May 2003 | B1 |
6574632 | Fox et al. | Jun 2003 | B2 |
6587850 | Zhai | Jul 2003 | B2 |
6591261 | Arthurs | Jul 2003 | B1 |
6654767 | McAnaney et al. | Nov 2003 | B2 |
6662178 | Lee | Dec 2003 | B2 |
6665656 | Carter | Dec 2003 | B1 |
6665670 | Winer et al. | Dec 2003 | B2 |
6694331 | Lee | Feb 2004 | B2 |
6751613 | Lee et al. | Jun 2004 | B1 |
6754873 | Law et al. | Jun 2004 | B1 |
6829603 | Chai et al. | Dec 2004 | B1 |
6832211 | Thomas et al. | Dec 2004 | B1 |
6862579 | Mathews et al. | Mar 2005 | B2 |
6879990 | Boyer et al. | Apr 2005 | B1 |
6940509 | Crow et al. | Sep 2005 | B1 |
6996273 | Mihcak et al. | Feb 2006 | B2 |
7054856 | Won et al. | May 2006 | B2 |
7089192 | Bracchita et al. | Aug 2006 | B2 |
7092961 | Minezaki et al. | Aug 2006 | B2 |
7099876 | Hetherington et al. | Aug 2006 | B1 |
7106329 | Miller et al. | Sep 2006 | B1 |
7111002 | Zhang et al. | Sep 2006 | B2 |
7188069 | Hagelin | Mar 2007 | B2 |
7194490 | Zee | Mar 2007 | B2 |
7216100 | Elliot | May 2007 | B2 |
7228288 | Elliot | Jun 2007 | B2 |
7242217 | Van Wageningen et al. | Jul 2007 | B2 |
7269566 | Elliott | Sep 2007 | B2 |
7292994 | Prokoski | Nov 2007 | B2 |
7320000 | Chitrapura | Jan 2008 | B2 |
7331016 | Williams et al. | Feb 2008 | B2 |
7433884 | Breitzman | Oct 2008 | B2 |
7536312 | Block | May 2009 | B2 |
7546265 | Donner | Jun 2009 | B1 |
7558749 | Chen | Jul 2009 | B2 |
7606757 | Poltorak | Oct 2009 | B1 |
20020002524 | Kossovsky et al. | Jan 2002 | A1 |
20020004775 | Kossovsky et al. | Jan 2002 | A1 |
20020022974 | Lindh | Feb 2002 | A1 |
20020035499 | Germeraad et al. | Mar 2002 | A1 |
20020046038 | Prokoski | Apr 2002 | A1 |
20020077835 | Hagelin | Jun 2002 | A1 |
20020082778 | Barnett et al. | Jun 2002 | A1 |
20020087442 | Reader | Jul 2002 | A1 |
20020099637 | Wilkinson et al. | Jul 2002 | A1 |
20020099638 | Coffman et al. | Jul 2002 | A1 |
20030036945 | Del Vecchio et al. | Feb 2003 | A1 |
20030065658 | Matsubayashi et al. | Apr 2003 | A1 |
20030078870 | Datar et al. | Apr 2003 | A1 |
20030126054 | Purcell, Jr. | Jul 2003 | A1 |
20030212572 | Poltorak | Nov 2003 | A1 |
20030217113 | Katz et al. | Nov 2003 | A1 |
20040010393 | Barney | Jan 2004 | A1 |
20040103112 | Colson et al. | May 2004 | A1 |
20050021434 | D'Loren | Jan 2005 | A1 |
20050071174 | Leibowitz et al. | Mar 2005 | A1 |
20050083850 | Sin et al. | Apr 2005 | A1 |
20050149420 | Hagelin | Jul 2005 | A1 |
20060036452 | Williams | Feb 2006 | A1 |
20060036453 | Williams | Feb 2006 | A1 |
20060036529 | Williams | Feb 2006 | A1 |
20060036632 | Williams | Feb 2006 | A1 |
20060036635 | Williams | Feb 2006 | A1 |
20060074867 | Breitzman | Apr 2006 | A1 |
20060122849 | Masuyama et al. | Jun 2006 | A1 |
20060218056 | Dickman | Sep 2006 | A1 |
20060224972 | Albrecht et al. | Oct 2006 | A1 |
20070073625 | Shelton | Mar 2007 | A1 |
20070073748 | Barney | Mar 2007 | A1 |
20070088738 | Barney et al. | Apr 2007 | A1 |
20070094297 | Barney | Apr 2007 | A1 |
20070150298 | Barney | Jun 2007 | A1 |
20070208669 | Rivette et al. | Sep 2007 | A1 |
20080091620 | Vollenweider et al. | Apr 2008 | A1 |
20080147541 | Jones | Jun 2008 | A1 |
Number | Date | Country |
---|---|---|
1 215 599 | Jun 2002 | EP |
WO 0075851 | Dec 2000 | WO |
WO 0135277 | May 2001 | WO |
Number | Date | Country | |
---|---|---|---|
20070094297 A1 | Apr 2007 | US |
Number | Date | Country | |
---|---|---|---|
60714713 | Sep 2005 | US |